|
注册号: Registration number: |
ChiCTR2600127152 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-25 15:33:30 |
|
注册时间: Date of Registration: |
2026-06-25 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于多模态评估的中枢- 外周磁刺激在脑卒中患者下肢运动功能的疗效研究 |
|
Public title: |
Efficacy of Central-Peripheral Magnetic Stimulation in Lower Extremity Motor Function Recovery in Stroke Patients: A Multimodal Assessment-Based Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于多模态评估的中枢- 外周磁刺激在脑卒中患者下肢运动功能的疗效研究 |
|
Scientific title: |
Efficacy of Central-Peripheral Magnetic Stimulation in Lower Extremity Motor Function Recovery in Stroke Patients: A Multimodal Assessment-Based Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黎淑茵 |
研究负责人: |
黎淑茵/宋振华 |
|
Applicant: |
Shuyin Li |
Study leader: |
Shuyin Li/ Zhenhua Song |
|
申请注册联系人电话: Applicant telephone: |
+86 136 7975 6847 |
研究负责人电话:
Study leader's |
+86 133 2208 4942 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
13679756847@163.com |
研究负责人电子邮件: Study leader's E-mail: |
a1974781010@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国山东省济南市长清区大学科技园大学路4655号 |
研究负责人通讯地址: |
海南省海口市人民大道43号 |
|
Applicant address: |
No. 4655 University Road, University Science Park, Changqing District, Jinan City, Shandong Province, China |
Study leader's address: |
No. 43 Renmin Avenue, Haikou, Hainan Province. |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
山东中医药大学 |
||
|
Applicant's institution: |
Shandong University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
海口市人民医院 |
||
|
Affiliation of the Leader: |
Haikou People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-(伦理)-466 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
海口市人民医院生物医学伦理委员会 |
||
|
Name of the ethic committee: |
Biomedical Ethics Committee of Haikou People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-12-25 00:00:00 | ||
|
伦理委员会联系人: |
邱英麒 |
||
|
Contact Name of the ethic committee: |
Yingqi Qiu |
||
|
伦理委员会联系地址: |
海南省海口市人民大道43号 |
||
|
Contact Address of the ethic committee: |
No. 43 Renmin Avenue, Haikou, Hainan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 138 0752 7211 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
海口市人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Haikou People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
海南省海口市人民大道43号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 43 Renmin Avenue, Haikou, Hainan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
本研究得到了脑科学与类脑智能技术国家重点研发计划(项目编号:2025ZD0215200)、国家自然科学基金(项目编号:32360196)、海南省重点研发计划(项目编号:ZDYF2025SHFZ023、ZDYF2022SHFZ275)、海南省自然科学基金(项目编号:825QN566)、海南省健康科技创新联合专项(项目编号:WSJK2026ZD290、WSJK2025QN045、WSJK2025QN046、WSJK2024QN021、WSJK2024QN113)及海南省临床医学中心(编号:0202067)的资助。 |
||||||||||||||||||||||
|
Source(s) of funding: |
This work was supported by the Brain Science and Brain-like Intelligence Technology-National Science and Technology Major Projects (Grant Nos. 2025ZD0215200), the National Natural Science Foundation of China (Nos. 32360196), the Key R&D Project of Hainan Province (Grant No. ZDYF2025SHFZ023, Grant No. ZDYF2022SHFZ275), the Hainan Natural Science Foundation (Grant No.825QN566), the Joint Program on Health Science & Technology Innovation of Hainan Province (WSJK2026ZD290, WSJK2025QN045, WSJK2025QN046, WSJK2024QN021, WSJK2024QN113) and the Hainan Province Clinical Medical Center (No. 0202067). |
||||||||||||||||||||||
|
研究疾病: |
脑卒中 |
||||||||||||||||||||||
|
Target disease: |
stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究通过重复经颅磁刺激(repetitive Transcranial Magnetic Stimulation, rTMS)联合重复外周磁刺激(repetitive Peripheral Magnetic Stimulation, rPMS)两种非侵入式的神经调控技术来探讨中枢-外周磁刺激对脑卒中恢复期患者的下肢运动功能障碍的临床疗效。通过设计一项严谨的随机对照试验,基于近红外脑功能成像(functional Near-Infrared Spectroscopy ,fNIRS)、表面肌电图(surface electromyography,sEMG)、多维运动捕捉系统以及相关的功能性评估量表构成多模态评估体系来观察并系统分析该联合疗法对脑卒中患者下肢运动功能、平衡功能、日常生活活动能力等功能恢复的影响,为卒中后康复提供新的思路和方法,并为未来的临床实践提供更多依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study investigates the clinical efficacy of combined central-peripheral magnetic stimulation using two non-invasive neuromodulation techniques—repetitive transcranial magnetic stimulation (rTMS) and repetitive peripheral magnetic stimulation (rPMS)—in addressing lower limb motor dysfunction in stroke recovery patients. Through a rigorously designed randomized controlled trial, a multimodal assessment system was established, incorporating functional near-infrared spectroscopy (fNIRS), surface electromyography (sEMG), multivariate motion capture systems, and relevant functional evaluation scales. This approach systematically examines the effects of the combined therapy on lower limb motor function, balance, activities of daily living, and other functional recovery outcomes in stroke patients, offering novel insights and methods for post-stroke rehabilitation while providing stronger evidence for future clinical practice. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.有心脏起搏器、颅内有金属植入物、冠状动脉支架植入史等rTMS禁忌; 2.腰部有金属植入物等rPMS禁忌; 3.有癫痫发作史、家族癫痫史; 4.合并心、肺、肝、肾和造血系统等严重原发性疾病; 5.妊娠状态。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Presence of cardiac pacemaker, intracranial metal implant, history of coronary artery stent insertion, or other contraindications to rTMS; 2. Presence of lumbar metal implant or other contraindications to rPMS; 3. History of epileptic seizure or family history of epilepsy; 4. Comorbid severe primary diseases of the heart, lung, liver, kidney, or hematopoietic system; 5. Pregnant state. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-01-01 00:00:00至 To 2027-01-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-01-05 00:00:00 至 To 2027-01-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用区组随机化方法。由不参与受试者和结局评估的独立统计人员使用 SPSS 软件生成随机序列,设定区组长度为6,按 1:1:1 的比例将受试者分配至三组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A block randomization method will be used. An independent statistician who is not involved in subject recruitment or outcome assessment will generate the random allocation sequence using SPSS software, with a block length of 6 and a 1:1:1 allocation ratio. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
为了确保盲法的实施,治疗人员、评估人员、统计分析人员独立工作。由于磁刺激器械的操作特性,治疗人员无法实施盲法;但为最大限度保持盲态,评估人员、数据管理人员与统计分析人员均对分组信息设盲。治疗人员仅负责按代码对应的方案干预,不参与评估或数据分析;评估人员仅收集结局指标,不知分组详情;统计分析人员仅接触组别代码,不知代码对应具体干预措施。所有盲法流程由独立统计人员监督执行。 |
|
Blinding: |
To ensure the implementation of masking, the treatment personnel, outcome assessors, and statistical analysts worked independently. Due to the operational characteristics of the magnetic stimulation device, masking of treatment personnel was not feasible; however, to maintain blinding to the greatest extent possible, the outcome assessors, data managers, and statistical analysts were all masked to group allocation information. Treatment personnel were responsible solely for administering interventions according to the assigned codes and took no part in outcome assessment or data analysis; outcome assessors collected outcome measures only and were unaware of group allocation details; statistical analysts had access only to group codes and were unaware of the specific interventions corresponding to those codes. All masking procedures were supervised and implemented by an independent statistician. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究计划在研究主要结果论文被接收/发表后 12 个月内(以先发生者为准),以受控访问方式提供数据。 拟共享数据类型包括去识别化的个体参与者数据及其数据字典/变量说明书;不包含可直接识别受试者的原始病历影像与证件信息。有意获取数据的学者请向通讯作者提交简短申请,说明研究目的、所需变量范围、预计分析方法及成果署名/引用方式。申请人须签署数据使用协议并承诺仅用于科学研究、不试图重新识别受试者、不二次转售/转授、引用本研究并在成果中致谢/引用数据来源。经研究团队在伦理与数据监管框架下审批通过后,以受控方式提供。研究团队保留在数据涉及敏感临床信息、超出原伦理授权范围或申请用途不符时的审批与拒绝权限。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
This study plans to provide the data via controlled access within 12 months after the acceptance/publication of the main results paper (whichever occurs first). The proposed shared data types include de-identified individual participant data and its data dictionary/variable documentation; original medical imaging and document information directly identifying subjects are excluded. Scholars seeking to obtain the data should submit a brief application to the corresponding author, specifying the research purpose, required variable scope, anticipated analytical methods, and authorship/ citation protocols. Applicants must sign a data usage agreement and commit to using the data solely for scientific research, avoiding any attempts to re-identify subjects, secondary reselling/transferring, citing this study, and acknowledging/citing the data source in their results. Access will be granted in a controlled manner after approval by the research team within the ethical and data governance framework. The research team reserves the right to approve or deny access when the data involves sensitive clinical information, exceeds the original ethical authorization scope, or does not align with the stated research purpose. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |